Evidence map›Paper›PMID 34616749›Full record

ArticleFrontiers in medicine2021

Case Report: Detection of Double ROS1 Translocations,

Long Xu, Xiaoxia Chen, Hong Huo, Yongye Liu, Xiaodan Yang, Dejian Gu, Mingming Yuan, Min Zhang, Rongrong Chen, Jiayin Wang and 1 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Detection ofFrontiers in cell and developmental biology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Long XuDepartment of Oncology, General Hospital of Northern Theater Command, Shenyang, China.
Xiaoxia ChenDepartment of Oncology, General Hospital of Northern Theater Command, Shenyang, China.
Hong HuoDepartment of Nephrology, The Chinese People's Liberation Army Rocket Force Characteristic Medical Center, Beijing, China.
Yongye LiuDepartment of Oncology, General Hospital of Northern Theater Command, Shenyang, China.
Xiaodan YangDepartment of Oncology, General Hospital of Northern Theater Command, Shenyang, China.
Dejian GuGeneplus-Beijing, Beijing, China.
Mingming YuanGeneplus-Beijing, Beijing, China.
Min ZhangGeneplus-Beijing, Beijing, China.
Rongrong ChenGeneplus-Beijing, Beijing, China.
Jiayin WangSchool of Computer Science and Technology, Xi'an Jiaotong University, Xi'an, China.
Zhendong ZhengDepartment of Oncology, General Hospital of Northern Theater Command, Shenyang, China.
General Hospital of Shenyang Military Region · CNXi'an Jiaotong University · CNChinese People's Liberation Army · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

crizotinibdouble ROS1 fusionlung adenocarcinomanext-generation sequencingnovel ROS1 fusion

Identifiers

PMID34616749
PMCPMC8488083
OpenAlexW3201550227

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.